Featured
Spotlight on Autoimmunity: KYSA-1 Phase 1 Trial of KYV-101 in Refractory Lupus Nephritis
Watch Time: 04:45
Learn more about KYSA-1, an open-label, Phase 1/2 clinical trial of KYV-101, an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy
Key Publications
Preclinical Development of KYV-201, an Investigational Allogeneic Anti-CD19 CAR T Cell for the Treatment of Autoimmune Disease
Mahne A, et al.
EULAR Congress 2024, Poster #POS0462
Serum Proteomic Analysis Identifies Markers Associated With Anti-CD19 CAR T Therapeutic Response in Autoimmune Diseases
Chou J, et al.
EULAR Congress 2024, Poster #POS0464
Development of Ingenui-T, a Rapid Autologous Chimeric Antigen Receptor (CAR)-T Manufacturing Solution Using Whole Blood, for Treatment of Autoimmune Disease
Anaya D, et al.
ISCT Annual Meeting 2024, Abstract #4070843
Serum Proteomic Analysis Identifies Markers Associated With Anti-CD19 CAR T Therapeutic Response in Autoimmune Diseases
Chou J, et al.
ASGCT 27th Annual Meeting 2024, Abstract #1820
Preclinical Development of KYV-201, an Investigational Allogeneic Anti-CD19 CAR T Cell for the Treatment of Autoimmune Disease
Mahne A, et al.
ASGCT 27th Annual Meeting 2024, Abstract #1810
CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis
Fischbach F, et al.
Med. Published online March 29, 2024
First Two US Patients With Lupus Nephritis (LN) Treated With Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy: Preliminary Results From the KYSA-1 Phase 1/2, Multicenter Study of KYV-101
Podoll A, et al.
14th European Lupus Meeting, 2024
Anti-CD19 CAR T cells for refractory myasthenia gravis
Haghikia A, et al.
Lancet Neurology 2023;22:P1104-1105
KYV-101, a Fully Human Anti-CD19 CAR T Cell Therapy, Demonstrates CAR-Mediated and CD19-Dependent Activity Against Autologous B Cells from Patients with Autoimmune Disease
Park S, et al.
ACR Convergence 2023, Abstract #0904
Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus
Mackensen A, et al.
Nat Med 2022;28:2424-2132
Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma
Brudno JN, et al.
Nat Med 2020;26:270-280
Meet Kyverna
June 29 – July 2, 2024
Helsinki, Finland
This year’s overarching theme is ‘Neuromodulation: advances and opportunities in neurological diseases’ and there will be a range of workshops and plenary sessions addressing this subject. Leading specialists will tackle hot topics in invasive and non-invasive neuromodulation in movement and cognitive disorders, chronic pain, and refractory epilepsy.
September 18 - 20, 2024
Copenhagen, Denmark
ECTRIMS 2024 is the premier meeting place for researchers, clinicians, and healthcare providers to collaborate on the next life-changing research and treatment options for people with MS and related diseases.
November 14 - 19, 2024
Washington D.C.
The Rheumatology Research Foundation is the largest private funding source for rheumatology research and training in the United States. ACR Convergence 2024 will be held November 14-19 at the Walter E. Washington Convention Center in Washington D.C.
Educational Videos
Watch Time: 05:01
Learn about current management of lupus nephritis and how current clinical trials are evaluating novel therapeutic approaches to address unmet needs in the treatment of lupus nephritis.
Watch Time: 09:45
Learn more about the current strategies for the management of lupus nephritis, from meticulous control of blood pressure, inflammation, to ensure that comprehensive care is kept in the picture to account for patient lifestyle and preference.